Stockholders' Equity - Narrative (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2025 USD ($) vote shares	Sep. 30, 2024 USD ($) shares	Dec. 31, 2024 shares	Nov. 08, 2024 shares
Subsidiary or Equity Method Investee [Line Items]
Common Stock, shares authorized (in shares)	300,000,000			300,000,000		300,000,000
Preferred Stock, shares authorized (in shares)	5,000,000			5,000,000		5,000,000
Number of votes per share | vote				1
Warrants outstanding (in shares)							3,871,557
Change in fair value of warrant liability (note 12) | $	$ 0	$ (2,243)		$ 0	$ (1,800)
Granted (in shares)				0	0
Number of shares issued for options exercised on a cash basis (in shares)				0	207,002
Exercise of stock options | $		198	$ 545		$ 700
Share-based compensation arrangement by share-based payment award, options, exercises in period, cashless basis (in shares)					38,014
Stock issued during period, stock options exercised, cashless basis, shares (in shares)					13,509
Equity-based compensation expense | $	5,300			$ 16,700	$ 10,600
Unrecognized compensation expense | $	35,800			$ 35,800
Recognition period (in years)				2 years
General and Administrative Expense
Subsidiary or Equity Method Investee [Line Items]
Equity-based compensation expense | $	4,600	100		$ 13,200	7,200
Cost of Sales
Subsidiary or Equity Method Investee [Line Items]
Equity-based compensation expense | $	$ 700	900		$ 3,500	3,400
Performance Percentage Greater Than or Equal to 75%
Subsidiary or Equity Method Investee [Line Items]
Performance payout percentage				200.00%
Performance Percentage Less Than 25%
Subsidiary or Equity Method Investee [Line Items]
Performance payout percentage				0.00%
Performance Percentage Greater Than or Equal to 25%
Subsidiary or Equity Method Investee [Line Items]
Performance payout percentage				50.00%
Performance Percentage Equal to 50%
Subsidiary or Equity Method Investee [Line Items]
Performance payout percentage				100.00%
Unvested restricted stock units
Subsidiary or Equity Method Investee [Line Items]
Granted (in shares)				2,498,000
Various Employees | Unvested restricted stock units
Subsidiary or Equity Method Investee [Line Items]
Granted (in shares)				1,579,775
Vesting period (in years)				3 years
Grant date fair value | $				$ 16,900
Non-Employee Directors | Unvested restricted stock units
Subsidiary or Equity Method Investee [Line Items]
Granted (in shares)				185,674
Vesting period (in years)				1 year
Grant date fair value | $				$ 1,700
Certain Employees | Performance Based Restricted Stock Unit
Subsidiary or Equity Method Investee [Line Items]
Granted (in shares)				732,379
Vesting period (in years)				3 years
Grant date fair value | $				$ 12,400
Term of relative total shareholder return v. defined peer group (in years)				3 years
Prior President
Subsidiary or Equity Method Investee [Line Items]
Equity-based compensation expense | $		$ (3,300)			$ (3,300)
2019 Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Shares authorized for issuance (in shares)	18,350,000			18,350,000
Stock available for issuance (in shares)	8,081,294			8,081,294